within Pharmacolibrary.Drugs.R_RespiratorySystem.R03A_AdrenergicsInhalants.R03AK12_SalmeterolAndBudesonide;

model SalmeterolAndBudesonide
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C(
    weight = 70,
    F = 1,
    Cl = 2.777777777777778e-05,
    adminDuration = 600,
    adminMass = 50 / 1000000,
    adminCount = 1,
    Vd = 0.16,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    Vdp = 0.4,
    k12 = 2.3611111111111114e-05,
    k21 = 2.3611111111111114e-05);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>SalmeterolAndBudesonide</td></tr><tr><td>ATC code:</td><td>R03AK12</td></tr><td>route:</td><td>inhalation</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>50</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>160</td><td>L</td></tr>
    <tr><td>clearance:</td><td>100</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>A fixed-dose combination of salmeterol, a long-acting beta-2 adrenergic agonist (LABA), and budesonide, an inhaled corticosteroid (ICS). This combination is used as a maintenance treatment for asthma and chronic obstructive pulmonary disease (COPD) to reduce inflammation and bronchodilation. It is approved and commonly used today for these indications.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters estimated for healthy adult subjects after inhalation based on published data for individual components; no direct published PK model for the fixed-combination inhaler product exists.</p><h4>References</h4><ol><li><p>Latorre, M, et al., &amp; Paggiaro, P (2015). Differences in the efficacy and safety among inhaled corticosteroids (ICS)/long-acting beta2-agonists (LABA) combinations in the treatment of chronic obstructive pulmonary disease (COPD): Role of ICS. <i>Pulmonary pharmacology &amp; therapeutics</i> 30 44–50. DOI:<a href=\"https://doi.org/10.1016/j.pupt.2014.10.006\">10.1016/j.pupt.2014.10.006</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/25445928/\">https://pubmed.ncbi.nlm.nih.gov/25445928</a></p></li><li><p>Kim, D, et al., &amp; Lockey, R (2009). Evaluation of combination long-acting beta-2 agonists and inhaled glucocorticosteroids for treatment of asthma. <i>Expert opinion on drug metabolism &amp; toxicology</i> 5(8) 933–940. DOI:<a href=\"https://doi.org/10.1517/17425250903127226\">10.1517/17425250903127226</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/19619072/\">https://pubmed.ncbi.nlm.nih.gov/19619072</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.R.R03AK12 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end SalmeterolAndBudesonide;
